Emerging role of IL-17 and Th17 cells in systemic lupus erythematosus

Copyright © 2014. Published by Elsevier Inc.

Bibliographische Detailangaben
Veröffentlicht in:Clinical immunology (Orlando, Fla.). - 1999. - 154(2014), 1 vom: 20. Sept., Seite 1-12
1. Verfasser: Martin, Jérôme C (VerfasserIn)
Weitere Verfasser: Baeten, Dominique L, Josien, Régis
Format: Online-Aufsatz
Sprache:English
Veröffentlicht: 2014
Zugriff auf das übergeordnete Werk:Clinical immunology (Orlando, Fla.)
Schlagworte:Journal Article Review IL-17 SLE Th17 Interleukin-17
LEADER 01000naa a22002652 4500
001 NLM238532747
003 DE-627
005 20231224114009.0
007 cr uuu---uuuuu
008 231224s2014 xx |||||o 00| ||eng c
024 7 |a 10.1016/j.clim.2014.05.004  |2 doi 
028 5 2 |a pubmed24n0795.xml 
035 |a (DE-627)NLM238532747 
035 |a (NLM)24858580 
035 |a (PII)S1521-6616(14)00131-4 
040 |a DE-627  |b ger  |c DE-627  |e rakwb 
041 |a eng 
100 1 |a Martin, Jérôme C  |e verfasserin  |4 aut 
245 1 0 |a Emerging role of IL-17 and Th17 cells in systemic lupus erythematosus 
264 1 |c 2014 
336 |a Text  |b txt  |2 rdacontent 
337 |a ƒaComputermedien  |b c  |2 rdamedia 
338 |a ƒa Online-Ressource  |b cr  |2 rdacarrier 
500 |a Date Completed 30.09.2014 
500 |a Date Revised 31.03.2022 
500 |a published: Print-Electronic 
500 |a Citation Status MEDLINE 
520 |a Copyright © 2014. Published by Elsevier Inc. 
520 |a Despite the success of targeted therapies in managing immune-mediated inflammatory diseases (IMIDs) such as RA, IBDs, MS and psoriasis, unmet needs for such approach in SLE are widely recognized. In the past 2years, exciting insights supporting previous lines of evidence on the role of the IL-23/IL-17 axis in SLE have emerged. This is of particular importance as IL-17 blockers have now moved successfully into the clinical space, as illustrated in psoriasis and ankylosing spondylitis. However, recent fundamental studies also highlighted unexpected aspects of IL-17/Th17 biology whose comprehension may prevent disappointing results of IL-17 targeting such as those obtained in Crohn's disease. Therefore, establishing a current picture of the IL-17 pre-clinical situation in SLE is timely in order to plan future proof-of-concept studies in human 
650 4 |a Journal Article 
650 4 |a Review 
650 4 |a IL-17 
650 4 |a SLE 
650 4 |a Th17 
650 7 |a Interleukin-17  |2 NLM 
700 1 |a Baeten, Dominique L  |e verfasserin  |4 aut 
700 1 |a Josien, Régis  |e verfasserin  |4 aut 
773 0 8 |i Enthalten in  |t Clinical immunology (Orlando, Fla.)  |d 1999  |g 154(2014), 1 vom: 20. Sept., Seite 1-12  |w (DE-627)NLM098196855  |x 1521-7035  |7 nnns 
773 1 8 |g volume:154  |g year:2014  |g number:1  |g day:20  |g month:09  |g pages:1-12 
856 4 0 |u http://dx.doi.org/10.1016/j.clim.2014.05.004  |3 Volltext 
912 |a GBV_USEFLAG_A 
912 |a SYSFLAG_A 
912 |a GBV_NLM 
912 |a GBV_ILN_11 
912 |a GBV_ILN_24 
912 |a GBV_ILN_350 
951 |a AR 
952 |d 154  |j 2014  |e 1  |b 20  |c 09  |h 1-12